Introduction
In childhood acute lymphoblastic leukemia (ALL), risk-adapted combination therapy has led to dramatic improvements in outcome, with five-year survival rates over 85% in most industrialized countries. 1 However, ALL relapse still carries a very poor prognosis and the majority of relapses continue to occur in patients without apparent "high risk" features. [2] [3] [4] Thus, more accurate risk classification of newly diagnosed disease is needed to reduce relapses and improve the overall outcome of ALL.
Prior efforts to improve risk stratification primarily focused on genetic variations of the tumor, or on assessment of early antileukemic response (upfront prednisone response 5 , minimal residual disease [MRD] after remission induction 6 ). The role of inherited genetic variation on treatment response in children with ALL has received increasing attention. 7 For instance, candidate gene studies have suggested that genetic polymorphisms in metabolizing enzymes (GSTM1) and transporters (ABCC4) of antileukemic agents affect treatment outcome. 8, 9 Recent studies also identified associations between sequence variation in cytokine and chemokine genes and early treatment response, 7, 10 indicating tumor-microenvironment interaction as one plausible mechanism by which host genetic variation affect ALL outcome. 11 Prognostic features of ALL are strongly dependent upon treatment, and the lack of "replication" of pharmacogenetic findings in chemotherapy trials (and particularly outside the context of clinical trials) may be attributed to modest differences in therapy among trials. To maximize the opportunity of identifying genotype-phenotype associations generalizable to diverse treatment regimens, we applied an iterative "discovery-vs-replication" genomic screen to a core panel of
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From frontline ALL trials in the Children's Oncology Group (COG) and at St. Jude Children's Research Hospital (St. Jude). Our goal was to agnostically test single nucleotide polymorphisms (SNPs) throughout the genome for their association with the risk of relapse in a large group of children with ALL (N=2,535) from diverse racial/ethnic backgrounds.
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Methods
Patients and treatment: Germline DNA samples were collected at remission in children with newly diagnosed ALL treated on St. Jude Children's Research Hospital Total Therapy XIIIB 12 and XV 13 , the Children's Oncology Group (COG) P9906, 14 or COG P9904/P9905 studies 14 ( Table 1 ). The studies were approved by the Institutional Review Boards and informed consent was obtained from the parents, the guardians or the patients, in accordance with the Declaration of Helsinki. ALL treatment regimens were as described for St. Jude 12, 13 and COG 14 protocols.
Genotyping and genetic ancestry:
Genotyping and quality control were performed as described previously. Briefly, germline DNA was genotyped using either the Affymetrix GeneChip human
Mapping 500K sets or SNP6.0 array. Genotyping calls were determined using the BRLMM 15 or the Birdseed algorithms, 16 for the 500K array and the SNP6.0 array, respectively. Genotypes were coded assuming an additive genetic model (based on the number of B alleles). Only SNPs common between both Affymetrix array platforms were interrogated in this study. We further excluded 26,303 SNPs due to low minor allele frequency (MAF<0.5%) or poor call rate (<95%), and 136 patients due to poor genotyping (call rate <95%).
European, African, Asian, and Native American (NA) genetic ancestries were estimated using To maximize the statistical power for detecting associations between SNP genotype and relapse risk, we performed a GWAS inclusive of all 2,535 patients. SNPs were individually tested for association with relapse by a two-step procedure. Firstly, Gray's test (stratifying on treatment arms) was applied to each SNP, and secondly, those achieving P <0.05 were subsequently analyzed using the Fine and Gray's cumulative incidence hazard rate regression model 19 including both genetic ancestry (European, African, Asian, and NA) and treatment arm as covariates, and genotypes were treated as ordinal variables under an additive genetic model. To balance false positive and false negative error rates, we examined the profile information criteria 20 and determined that the P value threshold was 4.4×10 -3 to declare SNPs significantly related to relapse hazard. To further prioritize top relapse SNPs, we applied an iterative resampling procedure to determine if a SNP was reproducibly associated with relapse ( Fig. 1 ). We
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From first split 2,535 patients at a 1:1 ratio into a discovery and a replication cohort, balancing on treatment arm, genetic ancestry, central nervous system (CNS) disease status, and treatment outcome. SNPs were individually tested in the discovery cohort for association with relapse by the two-step procedure (Gray's followed by Fine and Gray's regression model) as described above. Significant SNPs (at P < 4.4×10 -3 ) from the discovery cohort GWAS were tested for replication. In the replication cohort, a SNP was considered validated if its genotype was associated with relapse at the 0.05 significance level by both Gray's test and the hazard rate regression model. This discovery-replication procedure was repeated 100 times ( Fig. 1 
Association of relapse SNPs with additional prognostic phenotypes

Clinical presenting features
Patient characteristics at diagnosis have been associated with relapse risk. We assessed whether genotypes associated with relapse were also related to these prognostic patient characteristics. Associations between genotype and all four pharmacokinetic phenotypes were evaluated by linear regression tests.
Statistical and computational analyses were performed using R version 2.9.1 (www.r-project.org) and SAS software, version 9.2.
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Results
Identification of genomic loci associated with ALL relapse risk
Using an iterative re-sampling strategy, we tested which of 444,044 germline SNP genotypes were reproducibly associated with relapse across treatment regimens (Fig. 1) . Thus, dividing the 2,535 patients into a discovery and a replication cohort at a 1:1 ratio, we used the discovery cohort to perform a genome-wide screen and then filtered SNPs based on their association in the replication cohort (Fig. 1) . A total of 134 SNPs were successfully replicated in at least 10 of 100 rounds of discovery-replication tests (top 25 SNPs shown in Table 2 and full listing in Supplemental Table 1S ). These 134 SNPs, representing 88 independent genomic loci (pairwise r 2 <0.5, Supplemental Fig. 1S ), were also significant in a GWAS inclusive of all 2,535 patients (P<0.004), and were thus prioritized for subsequent analyses. Seventy-three of 134 SNPs were annotated to 43 genes (within 10kb of a gene), all of which were intronic except for a synonymous coding variant in the ATP8A2 gene (rs6491066).
Across the genome, the strongest association with relapse risk was observed at 14q22.1 in the PYGL gene (rs7142143). Each copy of the C allele at this PYGL intronic SNP (rs7142143) rendered a 3.6 fold increase in the risk of relapse (P=6.7×10 -9 , Fig. 2 ) and association of this SNP with relapse was replicated in 79 of 100 rounds of re-sampling ( Table 2 ).
Many GWASs of treatment response neglect to consider the confounding of germline SNP genotypes with known prognostic factors. Of 134 relapse SNPs, 73 were associated with one or more clinical presenting features that are recognized as prognostic in childhood ALL (P<0.05, Supplemental Table 1S ), indicating their independent associations with relapse risk.
Associations of relapse SNPs with MRD
Early reduction of leukemia burden, as determined by MRD status at the end of remission induction therapy, is highly prognostic for ALL relapse. However, the majority of relapses still occur among patients with negative MRD status 14 Fig. 2S ).
Relationships between relapse SNPs and pharmacologic phenotypes
To explore the mechanisms by which SNPs might influence treatment outcome of ALL, we examined the association of the 134 relapse SNPs with four pharmacokinetic and pharmacodynamic endophenotypes available in a subset of patients: methotrexate plasma clearance, intracellular accumulation of polyglutamated (active) methotrexate, dexamethasone plasma clearance, and asparaginase antibody levels. Three relapse SNPs were associated with methotrexate plasma clearance following high dose intravenous methotrexate, and all 3 genotypes related to low clearance (more drug exposure) as well as with lower risk of relapse.
Genotypes at 7 SNPs were associated with polyglutamated methotrexate levels in ALL blasts, 5 of which were associated with reduced levels of methotrexate polyglutamate and a higher relapse risk, including 3 SNPs within the PDE4B gene. Dexamethasone plasma clearance differed significantly by genotype at 4 relapse SNPs; 2 of these were within the ABC transporter gene ABCB1, both associated with higher dexamethasone clearance and a higher relapse risk (Fig. 3) .
Finally, 5 relapse SNPs were related to higher asparaginase antibody levels, 2 of which were associated with a higher relapse rate. Together, as summarized in Table 3, 14 of 134 relapse SNPs were significant for at least one of the four pharmacologic phenotypes in a manner consistent with a pharmacokinetically intuitive association with relapse (i.e., lower drug exposure translated into a higher risk of relapse).
For
Discussion
Although current risk classification schemes identify children with more aggressive ALL, a substantial portion of these high-risk patients still do not respond to more intensive chemotherapy. Conversely, a substantial portion of the children with ALL who eventually relapse are initially classified as low risk at diagnosis. 24 For instance, even for MRD (the best clinical predictor of relapse in childhood ALL), more than 50% of relapse cases exhibit undetectable levels of leukemia burden after initial therapy and therefore cannot be reclassified for more intense treatment. 3, 4, 14 For these reasons, it was particularly impressive that germline variations distinguished patients at risk of relapse even within the group showing negative MRD, indicating that these genetic factors can significantly improve current models of risk stratification.
Capitalizing on the near-population-based capture of childhood ALL patients in the US to clinical trials led by the COG and St. Jude, our study systematically identified germline genetic variations associated with risk of relapse among 2535 children with ALL, the largest group of children with cancer ever studied for genetic determinants of outcome. Nevertheless, the number of patients receiving identical therapy is too small to separate patients into simple "discovery-vsreplication" cohorts for traditional genome-wide outcome analyses. Because therapy so strongly affects the likelihood of relapse, each discovery and replication cohort must be balanced for therapy arms. Therefore, we developed an iterative re-sampling approach 25, 26 in which patients were divided into a discovery and a replication cohort 100 times, each time balancing on treatment arm, ancestry, CNS status, and treatment outcome. By conducting the study in this manner, the replicated SNPs would be expected to be robust for multiple types of therapy. In fact, 133 of 134 relapse SNPs selected using this approach maintained prognostic significance after adjusting for treatment regimens and patient characteristics. We conclude that germline SNPs were associated with risk of ALL relapse in this large cohort of newly diagnosed children with ALL, even among patients who were negative for MRD, and thus inherited SNP genotypes may be a useful additional feature for risk classification in this disease. 
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